Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/04/240   
Active ingredient: Rufinamide
Indication: Treatment of Lennox-Gastaut syndrome
Sponsor: Eisai Limited
European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Inovelon on 16/01/2007 with the number EU/1/06/378

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/10/2004 Orphan designation EMEA/OD/047/04 (2004)4188 of 20/10/2004